A B S T R A C T
Background. Urinary tract infections (UTIs) are common following kidney transplantation (KT); however, the influence of recurrent post-KT UTI (R-UTI) is not well-characterized. Methods. We compared graft outcomes, patient outcomes and multidrug-resistance rates between patients with no UTI, nonrecurrent UTI (NR-UTI) (urine sample containing >10 5 bacterial colony-forming units/mL) and R-UTI (!2 UTIs in any 6-month period or !3 UTIs in any 12-month period) post-KT in a retrospective cohort study (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) at Barnes-Jewish Hospital (St Louis, MO). All adult KT recipients were included and those experiencing mortality within 30 days of KT were excluded. Results. Of 2469 recipients included, 1835 (74.3%) had no UTI, 465 (18.8%) had NR-UTI and 169 (6.8%) had R-UTI. R-UTI was associated with poorer graft survival compared with NR-UTI [hazard ratio (HR) 1.45; 95% confidence interval (CI) 1.23-1.83; P < 0.001) and no UTI (HR 2.11; 95% CI 2.02-3.80; P < 0.001). This relationship persisted after adjusting for confounding factors in Cox regression (HR 2.01; 95% CI 1.53-2.66; P < 0.001). There was no difference in patient survival between no UTI and NR-UTI (HR 1.21; 95% CI 0.91-1.63; P ¼ 0.181); however, R-UTI was associated with poorer patient survival compared with nonrecurrent cases (HR 1.87; 95% CI 1.21-2.89; P ¼ 0.005). R-UTI were more likely to be caused by multidrug-resistant Gram-negative organisms (risk ratio 1.49; 95% CI 1.31-1.70; P < 0.001).
Conclusions. R-UTIs were associated with poorer graft and patient outcomes, as well as increased multidrug-resistance compared with nonrecurrent cases.
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I N T R O D U C T I O N
Urinary tract infections (UTIs) are common following kidney transplantation (KT) and are associated with significant morbidity and mortality in this population [1, 2] . While routine use of antimicrobial prophylaxis has decreased the incidence of these infections, UTI remains the most common infectious complication after KT [1] [2] [3] [4] [5] . These infections are particularly concerning given their association with poorer graft and patient survival, as well as increased hospitalization costs [1, 5] .
While associations between post-KT UTI and both graft and patient outcomes are well-described in the literature, the impact of recurrent post-KT UTI (R-UTI) is less clear [1, 6, 7] . The cumulative incidence of these infections varies from 3% to 30%, differing based on the case definition used and length of followup [1, 6] . Studies evaluating the association between R-UTI and graft outcomes have reported conflicting findings [8] [9] [10] . Moreover, the influence of these infections on patient outcomes is unknown [1, 6] . The majority of R-UTIs are caused by Gramnegative pathogens, which often exhibit resistance to commonly used agents such as trimethoprim-sulfamethoxazole and fluoroquinolones [3, 5, 9, 11] . However, the comparative microbiology of R-UTIs versus non-recurring infections has not been extensively evaluated.
To address these important gaps in the literature, the objectives of this study were to: post-KT UTI status and both graft and patient outcomes; and (ii) describe and compare the microbiology and antimicrobial resistance profiles between nonrecurrent post-KT UTI (NRUTIs) and R-UTIs.
M A T E R I A L S A N D M E T H O D S
Study population
This was a single-center, retrospective, observational cohort study of patients who underwent KT at Barnes-Jewish Hospital (Washington University Medical Center, St Louis, MO), an urban tertiary care academic medical center that performs over 200 KT annually and follows recipients lifelong, until failure of the graft or withdrawal of immunosuppression. All adult KT recipients from 1999 to 2014 were included and only those patients who experienced early mortality (within 30 days post-KT) were excluded from analyses. Patients with a post-KT urine sample revealing >10 5 bacterial colony-forming units/mL were identified as having a UTI. Symptoms of UTI were not directly assessed, although our program does not actively screen patients for asymptomatic bacteriuria beyond 3 months post-KT and only performs urinalysis and culture with clinical suspicion of UTI. This definition of UTI was chosen to be consistent with previous large-scale analyses of post-KT UTIs [12] [13] [14] [15] .
R-UTI were defined as !3 UTIs in any 12-month period or !2 UTIs in any 6-month period, irrespective of the causative organism [6, 7] . Significant care was taken to ensure persistent infections were not misclassified as recurrent cases. As such, UTIs caused by the same organism within a treatment period were considered persistent infections and not considered in the definition of recurrence. Non-bacterial UTIs were not assessed. This study was approved by the Washington University in St Louis institutional review board with a waiver of informed consent in accordance with the ethical standards of the Helsinki Declaration of 1975, as revised in 2000.
Data collection
Clinical data for patients meeting study criteria were queried from the electronic medical record (inpatient and outpatient) into an approved institution-specific KT database. Data collected included patient demographics, comorbidities, indication for KT, donor status, intraoperative records, blood type, cytomegalovirus (CMV) status, laboratory and microbiological data, immunosuppressant treatment data, antimicrobial treatment data, dialysis data, biopsy data and dates of death.
Outcomes
The primary outcome was overall graft survival. Graft failure was defined at the earliest reported date of return to long-term dialysis, re-transplantation or patient death. Other secondary outcomes included overall patient survival, graft function (evaluated yearly) and death-censored graft survival. For the analysis of death-censored graft survival, patients not yet experiencing graft failure on the date of death were censored at that time. Additionally, the microbiology and resistance patterns of causative bacterial pathogens were described, and the association between UTI status and multidrug-resistance was evaluated. Multidrug-resistance was defined according to United States Centers for Disease Control and Prevention definitions for multidrug-resistant organisms (MDROs) [13] .
Statistical analysis
Patients were categorized into three groups based on post-KT UTI status: (i) no UTI; (ii) NR-UTI; or (iii) R-UTI. Patient, donor and transplant-related characteristics were compared by v 2 for categorical data and analysis of variance (ANOVA) or Kruskal-Wallis test for continuous data. Graft and patient survival outcomes were compared using the Kaplan-Meier method (log-rank test) and univariable Cox regression. For multivariable analysis of graft survival (non-death-censored), Cox proportional hazards models were derived with variables selected using a backward stepwise approach. Variables associated with graft failure (P < 0.20) were eligible for entry into the model and only variables that significantly altered the association between UTI status and outcome, resulting in !10% change in the associated HR, were included in the final parsimonious model.
To evaluate the association between UTI status and graft function, mean estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal Disease (MDRD) equation was compared between groups by ANOVA with Tukey's post hoc test [16] . Unadjusted risk ratios for antimicrobial resistance patterns and multidrug resistance were compared by UTI status for Gram-negative and Gram-positive species at the case and patient level. Statistical analyses were performed using SPSS (IBM Corporation, Armonk, NY, USA; version 22) and SAS software (SAS Institute, Cary, NC, USA; version 9.2) with P < 0.05 considered statistically significant.
R E S U L T S
A total of 2494 KT recipients were transplanted during the specified observation period. After excluding recipients with early mortality (n ¼ 25), a total population of 2469 was included in the final analysis. The median duration of follow-up was 5.67 years [interquartile range (IQR) 3.12-9.21 years]. Over the course of the observation period, 634 KT recipients (25.7%) experienced !1 UTI. Of these individuals, 465 (73.3%) experienced NR-UTI and 169 (26.7%) experienced R-UTI. The median time to initial UTI was 4.42 months (IQR 0.46-31.4 months). The median time from initial UTI to R-UTI was 3.35 months (IQR 1.01-9.89 months). Overall, the cumulative incidence of R-UTI was 6.8% (n ¼ 169/2469) and the median time to R-UTI was 13.4 months (IQR 3.07-51.3 months) post-KT. Patient, donor and transplant-related characteristics were compared among KT recipients by UTI status ( Table 1) . As shown, there were many significant differences between groups with regard to these characteristics. Recipients experiencing R-UTI were more likely to be older, African-American, transplanted from a deceased donor, transplanted from an expanded criteria donor, have previously undergone a transplantation, have a panel reactive antibody >20%, have combined diabetes and hypertension Table 1 . Comparison of kidney transplant recipient, donor and transplant-related characteristics based on post-kidney transplant UTI status 
as the primary cause of end-stage renal disease and never have received trimethoprim-sulfamethoxazole prophylaxis.
Graft outcomes
Factors associated with graft failure included combined diabetes and hypertension or other/unknown cause of end-stage renal disease, higher mean serum creatinine at time of transplantation, more human leukocyte antigen mismatches, delayed graft function, acute rejection, transplant glomerulopathy, lack of trimethoprim-sulfamethoxazole prophylaxis and UTI status (Supplementary data, Table S1 ). A Kaplan-Meier curve depicting the effect of post-KT UTI status on the primary outcome of overall graft survival is displayed in Figure 1 . As shown, there were clear differences in graft survival based on post-KT UTI status (log-rank P < 0.001). Patients experiencing NR-UTI had a significantly greater risk of graft failure versus those that never developed a UTI [hazard ratio (HR) 1.45; 95% confidence interval (CI) 1.23-1.83; P < 0.001]. Patients experiencing Figure 2 depicts the mean eGFR by UTI status over the post-KT observation period. As shown, there were significant overall differences in graft function beginning 12 months after transplant and persisting for the remainder of follow-up. Patients developing NR-UTI had significantly worse graft function than patients with no UTI, but this difference was not consistent throughout the entirety of the posttransplant period. In contrast, R-UTI status was associated with significantly worse graft function compared with both no UTI and NR-UTI status for the duration of the observation period.
Death-censored graft survival significantly differed by post-KT UTI status (Figure 3 ; log-rank P ¼ 0.002). Patients experiencing R-UTI were significantly more likely to experience death-censored graft failure than those never experiencing a UTI (HR 1.80; 95% CI 1.13-2.85; P ¼ 0.002). There was also a statistically significant difference in the risk of death-censored graft failure between patients experiencing NR-UTI versus no UTI (HR 1.34; 95% CI 1.02-1.80; P ¼ 0.033). However, patients experiencing R-UTI were at no greater risk of death-censored graft failure than those experiencing NR-UTI (HR 1.33; 95% CI 0.86-2.06; P ¼ 0.173).
Patient outcomes
Overall patient survival significantly differed by post-KT UTI status (Figure 4 ; log-rank P < 0.001). No difference in overall patient survival was observed between patients experiencing NR-UTI versus those with no UTI (HR 1.21; 95% CI 0.91-1.63; P ¼ 0.181). However, R-UTI status was associated with significantly poorer overall survival compared with no UTI (HR 2.73; 95% CI 1.74-4.27; P < 0.001) and NR-UTI (HR 1.87; 95% CI 1.21-2.89; P ¼ 0.005).
Microbiology and antimicrobial resistance patterns
A total of 1017 individual culture-positive UTI cases were observed throughout the post-KT observation period. The vast majority of these infections were due to Gram-negative pathogens (n ¼ 775/1017; 76.2%), over half of which were caused by Escherichia coli (n ¼ 411/775; 53.0%). Overall, most post-KT UTI occurred in the outpatient setting (n ¼ 823/1017; 80.9%). Escherichia coli was more commonly encountered in the outpatient setting than the inpatient setting [42.6% (n ¼ 351/823) versus 30.9% (n ¼ 60/194); P ¼ 0.003]. Nearly all Gram- Overall, pathogens causing R-UTI were similar to those implicated in NR-UTI, with no statistically significant differences observed between the two groups for any organism category (Supplementary data, Figure S1 ). Gram-negative pathogens were not more frequently implicated in R-UTI than in NR-UTI There were pronounced differences in antimicrobial resistance patterns between nonrecurrent and recurrent Gramnegative post-KT UTI analyzed at the patient level (Table 3) . R-UTI status was associated with an increased risk of resistance to first-and third-generation cephalosporins, trimethoprimsulfamethoxazole, nitrofurantoin, fluoroquinolones, extendedspectrum b-lactams and aminoglycosides. Gram-negative post-KT UTI were significantly more likely to be caused by an MDRO in R-UTI cases. Analyzed at the case level, recurrent Gram-negative post-KT UTIs were more likely to be multidrugresistant, as well as resistant to first-generation cephalosporins and fluoroquinolones (Supplementary data, Table S2a ). There was no significant association between Gram-negative multidrug-resistant UTI and graft failure [63.0% versus 69.8%; risk ratio (RR) 1.09; 95% CI 0.97-1.24; P ¼ 0.175]. Among cases due to Gram-positive organisms, there was a significant association between R-UTI status and both vancomycin resistance and multidrug resistance, analyzed at the patient (Table 4) and case level (Supplementary data, Table S2b ). There were no other statistically significant differences in Gram-positive antimicrobial resistance patterns between groups analyzed at the case or patient level.
D I S C U S S I O N
The purpose of this study was to evaluate the association between post-KT UTI on graft and patient outcomes, with a focus on R-UTI cases. To our knowledge, the present investigation was the largest analysis to date assessing the impact of UTI in this population. In this retrospective study at a large-volume transplant center, we observed a stepwise increase in the risk of overall graft failure between patients with no UTI compared with those experiencing NR-UTI compared with those experiencing R-UTI following KT. R-UTIs were associated with an increased risk of graft failure (non-death-censored and death-censored), as well as poorer patient survival and graft function. In addition, R-UTIs were more likely to be caused by MDROs, including vancomycin-resistant Enterococcus (VRE) and extended-spectrum b-lactamase-producing Gram-negative pathogens.
Prior to the present study, the epidemiology and risk factors for R-UTI were poorly described [6] . Specifically, risk factors that differentiated recurrent from nonrecurrent cases were largely unknown, because most studies combined these patients into a seemingly homogenous group. Female gender, diabetes mellitus, ureteric stenting, re-transplantation, lack of antimicrobial prophylaxis and prolonged urinary catheterization have been linked to R-UTI in previous literature [6, 8, [17] [18] [19] . In the present study, we observed a number of risk factors associated with R-UTI that had not been previously described. These included increased age, African-American race and deceased donor status. These factors have generally been associated with the development of post-KT UTI; however, we found the level of risk associated with these factors differs between recurrent and nonrecurrent cases [1, 20, 21] .
Despite routine antimicrobial prophylaxis with trimethoprim-sulfamethoxazole, approximately one-quarter of patients overall developed at least one UTI over the course of the observation period, underscoring the difficulty in preventing these infections in this vulnerable population. At our institution, all KT recipients without a severe sulfonamide allergy receive trimethoprim-sulfamethoxazole for dual prophylaxis against Pneumocystis jirovecii and UTI. The intended duration Table 3 . Patient-level analysis of antimicrobial resistance patterns for Gram-negative organisms causing nonrecurrent or recurrent post-kidney transplant UTIs
Multidrug-resistant (!3 classes), a n (%) 139 (49. Corresponding clinical isolate resistant to at least four antimicrobial classes to which the organism would be inherently susceptible. of this prophylaxis is lifelong, although patients experiencing an adverse event to this agent may receive alternate Pneumocystis prophylaxis, which lacks activity against uropathogens. As a result of these study findings, our institution now uses oral cephalexin for UTI prophylaxis in patients who are unable to tolerate trimethoprim-sulfamethoxazole. The majority of post-KT UTI occurred early in the posttransplant period, which is consistent with prior research [4, 22] . The incidence of R-UTI we observed was relatively low, but also consistent with previous analyses [4, 7, 8, 17, 19, 20, 23, 24] . Notably, the incidence of R-UTI was similar to rates reported in other transplant centers in USA in which similar infection definitions and length of follow-up were used [6] . Previous studies investigating the impact of R-UTI on graft outcomes have reported conflicting findings [6] . In a study of $1400 KT recipients in France, R-UTI was not associated with graft loss, although the average length of follow-up was only 1 year [24] . A more recent study failed to find an association between R-UTI and kidney graft function [8] . In studies with longer durations of follow-up similar to the present investigation, R-UTIs have been associated with poorer graft survival [9, 10] .
The present study was unique from previous analyses in that we compared graft outcomes between both NR-UTI and R-UTI status and demonstrated appreciable differences between these groups. Another noteworthy finding was that patients experiencing R-UTI had significantly worse graft function than patients who only experienced NR-UTI. There was little difference in graft function between patients with no UTI versus those experiencing only NR-UTI. The underlying etiology for these findings is unclear, but may be related to kidney allograft fibrosis. Allograft fibrosis has been found to occur in 75% of patients who experience R-UTI, but is less common in nonrecurrent cases [25] .
A novel finding from the present study was that patients experiencing R-UTI had poorer overall survival compared with both patients experiencing no UTI as well as those experiencing NR-UTI. It is accepted that post-KT UTIs are generally associated with worse patient outcomes; however, we found that this association was most significant for R-UTI cases [10, 21] . That is, the association between post-KT UTI and poorer patient survival appears to be driven by recurrence and patients who experience an isolated NR-UTI are at no greater risk of death than those who never experience a UTI. We believe future studies of post-KT UTI and outcomes should account for this important distinction.
The microbiology of NR-UTI and R-UTI in the present study was similar. Consistent with previous analyses, Gramnegative pathogens were common and E. coli was the most frequently isolated species [17, 20] . There were profound differences noted in antimicrobial susceptibility patterns and R-UTIs were significantly more likely to be caused by MDROs. When analyzed at the patient level, there were significant increases in resistance rates in patients with R-UTI as compared with those with NR-UTI for all antimicrobial classes evaluated except for carbapenems. However, due to the low incidence of carbapenem resistance observed in this study, we were underpowered to make this comparison. Among Gram-positive post-KT UTI, VRE was more commonly isolated in R-UTI cases. Combined, these resistance data have important clinical implications and should help inform empiric treatment of R-UTI cases in the post-KT population [12, 16] .
The present study should be interpreted within the context of its limitations. This was a retrospective analysis and suffers from the potential biases inherent to such a design. This study was conducted at a single-transplant center; therefore, the results may not be wholly generalizable to centers with differing immunosuppression protocols and/or antimicrobial prophylaxis strategies, which may vary substantially. Microbiology and antimicrobial resistance patterns may also differ geographically. Additionally, we were unable to collect potentially important risk factors for graft and patient outcomes, such as length of post-KT urinary catheterization. The UTI definition used in the present study did not include an assessment of symptoms; however, this definition is consistent with previous analyses of post-KT UTIs [6, 7, [12] [13] [14] [15] . Because of this, we were unable to assess differences in symptomatology, such as fever and graft pain, which may influence outcomes. It should be considered that beyond 3 months post-KT, our institution does not actively screen recipients for asymptomatic bacteriuria and only performs urinalysis and culture with clinical suspicion for UTI. Of note, the observed incidence of UTI in our study was similar to that found when symptoms were assessed and included in the definition of UTI [1, 6] . As such, we do not suspect availability of this data would have significantly impacted the classification of the included recipients. Of note, there are data demonstrating that asymptomatic bacteriuria, particularly repeated episodes, may be associated with subsequent pyelonephritis and graft failure; however, optimal management of these cases is still unclear [26] [27] [28] . Due to the potential for incomplete or inconsistent documentation of UTI symptomology in the medical record, we believe this would be best assessed in a prospective manner. The large sample size and extended length of follow-up enhance the internal validity of this study and are noteworthy strengths.
In summary, we found that patients with R-UTI had significantly worse graft function and graft survival compared with both those with no UTI as well as NR-UTI. R-UTI, but not NR-UTI, was associated with poorer patient survival compared with no UTI. Therefore, the association between UTI and worse patient outcomes in the KT population appears to be driven by recurrent cases. R-UTIs were more likely to be caused by MDROs, posing unique treatment challenges. Future studies aimed at determining the optimal agent and duration of treatment of UTI are crucial to preserving graft and patient outcomes in the KT population.
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